Europe
To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
AstraZeneca released new data that shows Calquence as a monotherapy and combined with Roche’s anti-CD20 drug Gazyva significantly improved progression-free survival in previously untreated CLL.
Sanofi announced it is acquiring Synthorx for $68 per share in cash, a value of $2.5 billion. The deal has been unanimously approved by both companies’ boards.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Over the course of the past year, Novartis has seen significant success with the approval of five drugs that have blockbuster potential and the company sees an additional 25 potential blockbuster drugs in its pipeline.
Shares of France-based Ipsen are down more than 2% on the Euronext Paris exchange after the U.S. Food and Drug Administration placed a partial clinical hold on its investigational treatment for fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO).
FerGene, a gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, reported that its Phase III trial of nadofaragene firadenovec (rAd-IFN/Syn3) met its primary endpoint.
BEAT® Diabetes utilizes SugarBEAT® CGM data to provide holistic coaching services via user-friendly app to enhance outcomes for diabetic and pre-diabetic patients
Oxford, UK, December 5 2019 - Oxford City Council’s East Area Planning Committee has approved the detailed plans for two office/laboratory buildings on The Oxford Science Park’s Plot 16 comprising 168,000 sq ft.
Apogenix announced that new data on its lead immuno-oncology candidate asunercept will be presented in a poster at the ESMO Immuno-Oncology Congress 2019, held from December 11-14, 2019, at the Palexpo in Geneva, Switzerland.
PRESS RELEASES